Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Jun 9

PMID 32509577

Citations 24

Authors

Yujiro Hayashi

Kazutoshi Fujita

Kyosuke Matsuzaki

Marie-Lisa Eich

Eisuke Tomiyama

Makoto Matsushita

Yoko Koh

Kosuke Nakano

Cong Wang

Yu Ishizuya

Taigo Kato

Koji Hatano

Atsunari Kawashima

Takeshi Ujike

Motohide Uemura

Ryoichi Imamura

George J Netto

Norio Nonomura

Affiliations

Soon will be listed here.

Abstract

Recent studies showed the clinical utility of next-generation sequencing of urinary cell-free DNA (cfDNA) from patients with urothelial bladder cancer (UBC). In this study, we aimed to develop urinary cfDNA analysis by droplet digital PCR (ddPCR) as a high-throughput and rapid assay for UBC detection and prognosis. We analyzed urinary cfDNA of 202 samples from 2 cohorts. Test cohort was designed for investigating clinical utility of urinary cfDNA, and was composed of 74 samples from patients with UBC, and 52 samples of benign hematuria patients. Validation cohort was designed for validation and assessment of clinical utility comparing urinary cfDNA with UroVysion (Abbott, Illinois, USA), and was composed of 40 samples from patients with UBC, and 36 prospectively collected samples from patients under surveillance after surgery for urothelial carcinoma. We performed ddPCR analysis of hotspot gene mutations ( promoter and ). In the test cohort, the sensitivity of urinary cfDNA diagnosis was 68.9% (51/74) and the specificity was 100% in patients with UBC. The sensitivity increased to 85.9% when used in conjunction with urine cytology. In addition, patients with high C228T allele frequency (≥14%) had significantly worse prognosis in bladder tumor recurrence than patients with low C228T allele frequency or negative C228T ( = 0.0322). In the validation cohort, the sensitivity of urinary cfDNA was 57.5% (23/40) and the specificity was 100% in UBC patients. The sensitivity of the combination of urine cytology with our hotspot analysis (77.5%) was higher than that of urine cytology with UroVysion (68.9%). In the post-surgical surveillance group, patients positive for the C228T mutation had significantly worse prognosis for bladder tumor recurrence than mutation negative patients ( < 0.001). In conclusion, ddPCR analysis of urinary cfDNA is a simple and promising assay for the clinical setting, surpassing UroVysion for detection and prognosis determination in UBC.

Citing Articles

Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials.

Huang F, Di X, Bai M Front Bioeng Biotechnol. 2024; 12:1458362.

PMID: 39295845 PMC: 11408225. DOI: 10.3389/fbioe.2024.1458362.

Novel method for detecting frequent TERT promoter hot spot mutations in bladder cancer samples.

Kovacs A, Sukosd F, Kuthi L, Boros I, Vedelek B Clin Exp Med. 2024; 24(1):192.

PMID: 39141194 PMC: 11324672. DOI: 10.1007/s10238-024-01464-3.

Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review.

Parrao D, Lizana N, Saavedra C, Larranaga M, Lindsay C, San Francisco I Curr Oncol. 2024; 31(4):2201-2220.

PMID: 38668066 PMC: 11048875. DOI: 10.3390/curroncol31040163.

Plasma-Derived Cell-Free DNA as a Biomarker for Early Detection, Prognostication, and Personalized Treatment of Urothelial Carcinoma.

Bhalla S, Passarelli R, Biswas A, De S, Ghodoussipour S J Clin Med. 2024; 13(7).

PMID: 38610824 PMC: 11012937. DOI: 10.3390/jcm13072057.

Morphology, immunohistochemistry characteristics, and clinical presentation of microcystic urothelial carcinoma: a series of 10 cases.

Su W, Sui W, Cheng X, Zong Y, Qin Y, Cui F Diagn Pathol. 2023; 18(1):94.

PMID: 37598154 PMC: 10439560. DOI: 10.1186/s13000-023-01381-1.

References

Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M, Clark P . Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(10):1240-1267. DOI: 10.6004/jnccn.2017.0156. View

Lotan Y, Roehrborn C . Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003; 61(1):109-18; discussion 118. DOI: 10.1016/s0090-4295(02)02136-2. View

Min J, Shay J . TERT Promoter Mutations Enhance Telomerase Activation by Long-Range Chromatin Interactions. Cancer Discov. 2016; 6(11):1212-1214. PMC: 5111399. DOI: 10.1158/2159-8290.CD-16-1050. View

Eich M, Pena M, Springer S, Taheri D, Tregnago A, Salles D . Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. Mod Pathol. 2019; 32(10):1544-1550. PMC: 6872189. DOI: 10.1038/s41379-019-0276-y. View

Nguyen D, Taheri D, Springer S, Cowan M, Guner G, Mendoza Rodriguez M . High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Arch. 2016; 469(4):427-34. PMC: 5561427. DOI: 10.1007/s00428-016-2001-2. View

Hayashi Y, Fujita K . A new era in the detection of urothelial carcinoma by sequencing cell-free DNA. Transl Androl Urol. 2020; 8(Suppl 5):S497-S501. PMC: 6989842. DOI: 10.21037/tau.2019.08.26. View

Ward D, Gordon N, Boucher R, Pirrie S, Baxter L, Ott S . Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. BJU Int. 2019; 124(3):532-544. PMC: 6772022. DOI: 10.1111/bju.14808. View

Kinde I, Munari E, Faraj S, Hruban R, Schoenberg M, Bivalacqua T . TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013; 73(24):7162-7. PMC: 3966102. DOI: 10.1158/0008-5472.CAN-13-2498. View

10.

Stern J, Theodorescu D, Vogelstein B, Papadopoulos N, Cech T . Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev. 2015; 29(21):2219-24. PMC: 4647555. DOI: 10.1101/gad.269498.115. View

11.

Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V . Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013; 4:2185. DOI: 10.1038/ncomms3185. View

12.

Satyal U, Srivastava A, Abbosh P . Urine Biopsy-Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer. Front Oncol. 2019; 9:1266. PMC: 6877686. DOI: 10.3389/fonc.2019.01266. View

13.

Sokolova I, Halling K, Jenkins R, Burkhardt H, Meyer R, Seelig S . The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2001; 2(3):116-23. PMC: 1906906. DOI: 10.1016/S1525-1578(10)60625-3. View

14.

Pena M, Tregnago A, Eich M, Springer S, Wang Y, Taheri D . Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Virchows Arch. 2017; 471(6):761-767. DOI: 10.1007/s00428-017-2164-5. View

15.

Sherry S, Ward M, Kholodov M, Baker J, Phan L, Smigielski E . dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2000; 29(1):308-11. PMC: 29783. DOI: 10.1093/nar/29.1.308. View

16.

Chiba K, Lorbeer F, Shain A, McSwiggen D, Schruf E, Oh A . Mutations in the promoter of the telomerase gene contribute to tumorigenesis by a two-step mechanism. Science. 2017; 357(6358):1416-1420. PMC: 5942222. DOI: 10.1126/science.aao0535. View

17.

Chang S, Boorjian S, Chou R, Clark P, Daneshmand S, Konety B . Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016; 196(4):1021-9. DOI: 10.1016/j.juro.2016.06.049. View

18.

Springer S, Chen C, Pena M, Li L, Douville C, Wang Y . Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife. 2018; 7. PMC: 5860864. DOI: 10.7554/eLife.32143. View

19.

Yoshida T, Kates M, Fujita K, Bivalacqua T, McConkey D . Predictive biomarkers for drug response in bladder cancer. Int J Urol. 2019; 26(11):1044-1053. DOI: 10.1111/iju.14082. View

20.

Dudley J, Schroers-Martin J, Lazzareschi D, Shi W, Chen S, Esfahani M . Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. Cancer Discov. 2018; 9(4):500-509. PMC: 6467650. DOI: 10.1158/2159-8290.CD-18-0825. View